Ralph BSc - Genelux Common Head Affairs
| GNLX Stock | 2.55 0.09 3.66% |
Executive
Ralph BSc is Head Affairs of Genelux Common
| Age | 67 |
| Address | 2625 Townsgate Road, Westlake Village, CA, United States, 91361 |
| Phone | 805 267 9889 |
| Web | https://www.genelux.com |
Genelux Common Management Efficiency
The company has return on total asset (ROA) of (0.4461) % which means that it has lost $0.4461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8857) %, meaning that it created substantial loss on money invested by shareholders. Genelux Common's management efficiency ratios could be used to measure how well Genelux Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2024. Return On Capital Employed is likely to rise to -1.08 in 2024. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 25.4 M in 2024, whereas Net Tangible Assets are likely to drop (31.3 M) in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Paul Reider | Coherus BioSciences | 54 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Theresa Lavallee | Coherus BioSciences | 58 | |
| Robert MD | Lyra Therapeutics | N/A | |
| Andy Rittenberg | Coherus BioSciences | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Michael Chen | Coherus BioSciences | N/A | |
| Cheston Turbyfill | Coherus BioSciences | N/A | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| Jami Taylor | Coherus BioSciences | N/A | |
Management Performance
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.45 |
Genelux Common Leadership Team
Elected by the shareholders, the Genelux Common's board of directors comprises two types of representatives: Genelux Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genelux. The board's role is to monitor Genelux Common's management team and ensure that shareholders' interests are well served. Genelux Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genelux Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ralph BSc, Head Affairs | ||
| Sean JD, General Secretary | ||
| Lourie Zak, Chief Officer | ||
| Joseph Cappello, Chief Officer | ||
| Thomas JD, CEO Chairman | ||
| Caroline Jewett, VP Quality | ||
| Yong Yu, Senior Development | ||
| Pr MD, Chief Officer |
Genelux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genelux Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 52.95 M | ||||
| Shares Outstanding | 34.54 M | ||||
| Shares Owned By Insiders | 16.28 % | ||||
| Shares Owned By Institutions | 15.70 % | ||||
| Number Of Shares Shorted | 1.43 M | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 10,620 X | ||||
| Revenue | 170 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.